Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bacteroides thetaiotaomicron - 4D Pharma

Next Previous
Drug Profile

Bacteroides thetaiotaomicron - 4D Pharma

Alternative Names: CJRB 203; MRx 1233; Thetanix

Latest Information Update: 18 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GT Biologics
  • Developer 4D Pharma PLC
  • Class Anti-inflammatories; Bacteria
  • Mechanism of Action Bacteria replacements; Immunomodulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I Crohn's disease
  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 18 Jan 2024 Bacteroides thetaiotaomicron is still in phase I trial for Crohn's disease (In adolescents) in United Kingdom (PO) (CJ Bioscience pipeline, January 2024)
  • 18 Jan 2024 Bacteroides thetaiotaomicron is still in preclinical trials for Inflammatory-bowel-diseases in United Kingdom (PO) (CJ Bioscience pipeline, January 2024)
  • 05 Oct 2021 Bacteroides thetaiotaomicron is still in phase I trials for Crohn’s disease in United Kingdom (4D pharma pipeline, October 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top